Table 1.
Vaccine efficacy of RZV.
| Vaccine efficacy against: | Vaccine efficacy | 95% CI | Reference |
|---|---|---|---|
| HZ in immunocompetent adults aged 50+ years | 97.2% | 93.7, 99.0 | 55 |
| HZ in immunocompetent adults aged 70+ years | 91.3% | 86.8, 94.5 | 56 |
| PHN in immunocompetent adults aged 70+ years | 88.8% | 68.7, 97.1 | 56 |
| HZ in immunocompetent adults aged 50+, year 10 post-vaccinationa | 73.2% | 46.9, 87.6 | 65 |
| HZ burden of illness (i.e. pain) in immunocompetent adults aged 50+ years | 98.4% | 92.2, 100 | 33 |
| HZ burden of illness in immunocompetent adults aged 70+ years | 92.1% | 90.4, 93.8 | 33 |
| HZ burden of interference with activities of daily living in immunocompetent adults aged 50+ years | 99.1% | 86.2, 100 | 33 |
| HZ burden of interference with activities of daily living in immunocompetent adults aged 70+ years | 90.3% | 88.5, 92.1 | 33 |
| HZ in frail individuals | 90.2% | 75.4, 97.0 | 62 |
| HZ in pre-frail individuals | 90.4% | 84.4, 94.4 | 62 |
| HZ in HSCT recipients | 68.2% | 55.6, 77.5 | 63 |
| HZ in patients with haematological malignancies | 87.2% | 44.3, 98.6 | 64 |
| HZ burden of illness in HSCT recipients | 82.5% | 73.6, 91.4 | 74 |
| HZ burden of interference with activities of daily living in HSCT recipients | 82.8% | 73.3, 92.3 | 74 |
CI confidence interval, HSCT hematopoietic stem cell transplantation, HZ herpes zoster; PHN post-herpetic neuralgia, RZV recombinant zoster vaccine.
aData accrual for year 10 is still ongoing65.